View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 18, 2004
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
New York 0-16093 16-0977505
- ------------------------------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
525 French Road
Utica, New York 13502
---------------------
(Address of principal executive offices, including zip code)
(315) 797-8375
--------------
(Registrant's telephone number, including area code)
Item 5. Other Events
On August 18, 2004, CONMED Corporation (Nasdaq: CNMD) announced that it had
entered into an agreement to acquire certain products comprising the Endoscopic
Technologies Division of C.R. Bard, Inc. (NYSE: BCR). The acquired assets
consist of a comprehensive line of single-use medical devices employed by
gastro-intestinal (GI) and pulmonary physicians to diagnose and treat diseases
of the digestive tract and lungs using minimally invasive endoscopic techniques.
CONMED Corporation intends to finance the acquisition using approximately $30
million of its cash on hand and borrowings under its revolving credit facility.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CONMED CORPORATION
(Registrant)
By:/s/ Robert D. Shallish, Jr.
------------------------------
Vice President-Finance and
Chief Financial Officer
Date: August 20, 2004